These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 8640806)
41. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649 [TBL] [Abstract][Full Text] [Related]
42. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Eng C; Mulligan LM; Healey CS; Houghton C; Frilling A; Raue F; Thomas GA; Ponder BA Cancer Res; 1996 May; 56(9):2167-70. PubMed ID: 8616867 [TBL] [Abstract][Full Text] [Related]
43. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Gallel P; Pallares J; Dolcet X; Llobet D; Eritja N; Santacana M; Yeramian A; Palomar-Asenjo V; Lagarda H; Mauricio D; Encinas M; Matias-Guiu X Hum Pathol; 2008 Jul; 39(7):994-1001. PubMed ID: 18508109 [TBL] [Abstract][Full Text] [Related]
44. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. Barletta JA; Nosé V; Sadow PM Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588 [TBL] [Abstract][Full Text] [Related]
45. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. Mulligan LM; Marsh DJ; Robinson BG; Schuffenecker I; Zedenius J; Lips CJ; Gagel RF; Takai SI; Noll WW; Fink M J Intern Med; 1995 Oct; 238(4):343-6. PubMed ID: 7595170 [TBL] [Abstract][Full Text] [Related]
46. Rare RET Variant p.D707E in a Chinese Pedigree with Hereditary Medullary Thyroid Carcinoma. Zhang L; Li X; Li Q; Ge S; Chen M; Huang S; Chen B; Li P; Teng B; Xu J; Zhao S; Qi F; Zhang Y Pathobiology; 2017; 84(3):152-160. PubMed ID: 27798940 [TBL] [Abstract][Full Text] [Related]
47. RET codon 609 mutations: a contribution for better clinical managing. Mian C; Sartorato P; Barollo S; Zane M; Opocher G Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):33-6. PubMed ID: 22584703 [TBL] [Abstract][Full Text] [Related]
48. 27-bp deletion in the ret proto-oncogene as a somatic mutation associated with medullary thyroid carcinoma. Kalinin V; Frilling A J Mol Med (Berl); 1998 Apr; 76(5):365-7. PubMed ID: 9587071 [TBL] [Abstract][Full Text] [Related]
50. Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas. Shan L; Nakamura M; Nakamura Y; Utsunomiya H; Shou N; Jiang X; Jing X; Yokoi T; Kakudo K Jpn J Cancer Res; 1998 Sep; 89(9):883-6. PubMed ID: 9818022 [TBL] [Abstract][Full Text] [Related]
51. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression. Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007 [TBL] [Abstract][Full Text] [Related]
55. Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients. Lesueur F; Cebrian A; Cranston A; Leyland J; Faid TM; Clements MR; Robledo M; Whittaker J; Ponder BA J Clin Endocrinol Metab; 2005 Jun; 90(6):3454-7. PubMed ID: 15741265 [TBL] [Abstract][Full Text] [Related]
56. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma. Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591 [TBL] [Abstract][Full Text] [Related]
57. Identification of two novel mutations in the RET proto-oncogene in the same family. Pazaitou-Panayiotou K; Giatzakis C; Koutsodontis G; Vratimos A; Chrisoulidou A; Konstantinidis T; Kamakari S Thyroid; 2010 Apr; 20(4):401-6. PubMed ID: 20373984 [TBL] [Abstract][Full Text] [Related]
58. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations. Chang TC; Wu SL; Hsiao YL Acta Cytol; 2005; 49(5):477-82. PubMed ID: 16334022 [TBL] [Abstract][Full Text] [Related]
59. [Medullary thyroid carcinoma in children]. Berdelou A; Hartl D; Al Ghuzlan A; Mirghani H; Chougnet C; Baudin E; Schlumberger M; Leboulleux S Bull Cancer; 2013; 100(7-8):780-8. PubMed ID: 23831771 [TBL] [Abstract][Full Text] [Related]
60. Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Carson EB; McMahon M; Baylin SB; Nelkin BD Cancer Res; 1995 May; 55(10):2048-52. PubMed ID: 7743500 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]